Uncle Sam Just Opened a File on China's Biotech Playbook
The U.S. International Trade Commission just launched a formal investigation into China's biotech subsidies, covering everything from gene sequencing to drug ingredients. It won't trigger tariffs on its own, but its January 2027 report could hand Washington the ammunition for the next major escalation in the biotech cold war.
Think of the U.S. International Trade Commission as the federal government's research librarian with subpoena power. It doesn't slap tariffs on anyone. It doesn't ban imports. What it does is build the case file that other people use to do those things.
And it just opened a brand-new file on China's biotech sector.
The USITC announced Investigation No. 332-610, a formal probe into Chinese state support and pricing practices across biotechnology. The agency will examine whether Beijing's subsidies are warping competition and eating into American market share. A report is expected by January 22, 2027, which means this slow-burning fuse will reach Congress right as the next legislative cycle heats up.
This isn't a tariff. It's not a ban. But if you've been tracking the escalating U.S.-China biotech cold war, this is the investigative groundwork that could power the next round of restrictions.
The Scope Is Broader Than You'd Think
The investigation isn't just about pills and vaccines. The USITC is casting a wide net across three specific areas: genomic sequencing, synthetic biology, and active pharmaceutical ingredient (API) manufacturing. That covers everything from the machines reading your DNA to the chemical building blocks inside your medicine cabinet.
The probe will ask a deceptively simple question: is Chinese government support giving its biotech companies an unfair price advantage, and is that hurting American producers?
The answer, based on existing evidence, is almost certainly going to be complicated. Research from MERICS (a leading European China-policy think tank) estimates that public funding for Chinese biotech research has totaled at least 20 billion yuan (roughly €2.6 billion). That's just the national-level number. Local governments pile on with their own incentives: land concessions, tax rebates, equipment subsidies, clinical trial support, and low-interest loans.
Shanghai alone offers a buffet of financial support for innovative drug R&D and major industrial projects. It's the biotech equivalent of a city building a new stadium to lure an NFL team, except the "stadium" is a biomanufacturing hub and the "team" is a gene-sequencing giant.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Why This Investigation Matters More Than It Looks
A Section 332 study, which is the formal name for this type of probe, doesn't automatically change any trade rules. Think of it like a grand jury investigation: no verdict yet, but the findings can be used to build a much bigger case. The National Security Commission on Emerging Biotechnology (NSCEB) praised the investigation, saying that if the ITC finds evidence of Chinese market manipulation, the findings could support "subsequent executive branch action" to "level the playing field."
Translation: this report could become ammunition for tariffs, procurement bans, or new legislation.
China, predictably, pushed back. The China Chamber of Commerce argued the probe lacks sufficient justification and warned against treating China's biotech growth as inherently threatening. Their counter-argument is that lower Chinese prices might simply reflect efficiency and supply-chain advantages rather than unfair subsidies.
It's a fair point, and the ITC will have to wrestle with it. But the political winds in Washington aren't blowing in Beijing's favor right now.
The BIOSECURE Backdrop
To understand why this investigation landed now, you need to rewind about two years.
In December 2025, Congress passed the BIOSECURE Act as part of the annual defense spending bill. The law restricts U.S. government contracts and procurement involving certain Chinese biotech firms deemed national security risks through a designation process tied to the DoD 1260H list and OMB criteria.
The fallout has been real but uneven. WuXi AppTec's stock cratered when the legislation first gained traction in 2024. Its cell and gene therapy unit, WuXi Advanced Therapies, blamed the act for a 17% revenue decline through the third quarter of that reporting period. The company even explored selling its pharma operations as the restrictions loomed.
But the full BIOSECURE restrictions likely won't kick in until 2027 or later, because the government still needs to finalize procurement rules and agency guidance. It's a law that exists on paper but hasn't fully materialized in practice, like a gym membership in January.
In June 2026, the Pentagon added WuXi AppTec to its list of companies with alleged Chinese military connections. A federal judge later blocked that designation, ruling the government lacked sufficient evidence, which gave WuXi temporary relief. The legal back-and-forth shows just how contested this terrain remains.
The Supply Chain Problem Nobody Wants to Talk About
Here's where it gets uncomfortable for the U.S. biotech industry. Nearly 80% of American biotech firms had ties to at least one Chinese contract development and manufacturing organization (CDMO) in 2025. WuXi AppTec alone is reportedly involved in producing roughly a quarter of medicines used in the U.S., according to a Health-ISAC report cited by Reuters.
Those aren't numbers you can unwind overnight. Switching CDMOs isn't like switching your coffee order. It means requalifying manufacturing sites, transferring proprietary technology, absorbing delays, and paying significantly higher costs. For small biotechs running a single clinical program, that kind of disruption can be existential.
And WuXi's U.S. business keeps growing despite the political headwinds. In the first nine months of 2025, its U.S. revenue rose 31.9% to about $3.1 billion. American customers accounted for roughly 68% of the company's total revenue through the first three quarters of 2025. The dependency runs both ways: WuXi needs the U.S. market, and the U.S. market, for now, still needs WuXi.
Two Tracks, One Industry
The practical result of all this pressure is an emerging two-track supply chain. U.S. biopharma companies are starting to diversify away from Chinese CDMOs and dual-source their most critical programs. Non-Chinese manufacturers like Samsung Biologics stand to benefit from the reshuffling, though no specific U.S. restrictions target South Korean companies.
Meanwhile, Chinese service providers face growing compliance friction, potential contract losses, and pressure to either localize operations or divest U.S.-exposed assets. WuXi's exploration of selling its pharma operations is a preview of what corporate restructuring under geopolitical stress looks like.
But nearly 100 publicly announced agreements between Chinese and U.S. biotech firms have been recorded since the start of 2025. The money is still flowing, even as the regulatory walls rise. That contradiction is fueling calls in Congress to scrutinize not just procurement, but licensing deals and outbound investment as well.
Some lawmakers want to add biotechnology to the Treasury Department's outbound investment screening rules, which currently focus on semiconductors and AI. If that happens, even private-sector deals between U.S. and Chinese biotech companies could face government review.
The Bigger Chess Game
Zoom out, and the ITC investigation is one piece of a much larger strategic puzzle. Washington is debating whether to pair its defensive moves (restrictions, bans, screening) with offensive ones (investment, incentives, industrial policy). Think of it as the biotech version of the CHIPS Act, which poured tens of billions into domestic semiconductor manufacturing.
The NSCEB has recommended at least $15 billion over five years to attract private capital into U.S. biotech capacity. So far, Congress hasn't committed to anything near those numbers.
China, for its part, is doubling down. Its 2026 Five Year Plan explicitly prioritizes biomedicine, biomanufacturing, and pharmaceuticals. Regulatory reforms are designed to accelerate market entry and speed up human clinical data collection. Beijing isn't waiting to see what Washington decides; it's building while America debates.
What Happens Next
The ITC's public hearing already took place in late May, and the deadline for written submissions passed in July. Now the commission is digesting the evidence and writing its report. When that report drops in January 2027, it will land on the desks of lawmakers who are already primed to act.
The question isn't whether U.S.-China biotech tensions will escalate. They will. The question is whether the escalation takes the form of targeted restrictions (like BIOSECURE) or something broader: sector-wide tariffs, investment screens, or even a full-blown industrial policy push.
For biotech companies caught in the middle, the playbook is painfully clear: diversify your supply chain, know your exposure, and don't assume that today's Chinese manufacturing partner will be available to you in 2028. The ITC isn't dropping a bomb. It's drawing the map that tells everyone else where to aim.
Deals & M&A
4 min read
Tarsus Just Bet $800 Million on a Disease With Zero Treatments
Tarsus Pharmaceuticals is spending up to $800 million to acquire Alkeus and its late-stage Stargardt disease therapy, a rare eye condition with zero approved treatments. It's a bold bet on rare disease pricing in a market where nobody has planted a flag yet.
